Biological drug duo delivers one-two tumor punch

Jeffrey A. Sosman*, James W. Mier

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

3 Scopus citations


Interleukin (IL)-2 can shrink tumors in patients with refractory melanoma and renal cancer, two of the deadliest types of solid tumors, but the use of IL-2 is limited by its high toxicity. A new drug reduces the side effects in mouse models and boosts the tumor-busting capacity of IL-2.

Original languageEnglish (US)
Pages (from-to)649-650
Number of pages2
JournalNature Medicine
Issue number6
StatePublished - Jun 1 2003

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Biological drug duo delivers one-two tumor punch'. Together they form a unique fingerprint.

Cite this